Aptevo Therapeutics Inc. APVO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.69M | 11.84M | 11.77M | 11.81M | 10.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.89M | 26.67M | 26.31M | 26.70M | 24.30M |
| Operating Income | -26.89M | -26.67M | -26.31M | -26.70M | -24.30M |
| Income Before Tax | -26.41M | -26.26M | -25.97M | -26.47M | -24.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.41 | -26.26 | -25.97 | -26.47 | -24.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.41M | -26.26M | -25.97M | -26.47M | -24.03M |
| EBIT | -26.89M | -26.67M | -26.31M | -26.70M | -24.30M |
| EBITDA | -26.69M | -26.46M | -26.07M | -26.47M | -24.04M |
| EPS Basic | -56.42 | -202.40 | -195.99 | -191.42 | -151.29 |
| Normalized Basic EPS | -32.08 | -123.31 | -119.36 | -115.53 | -94.55 |
| EPS Diluted | -56.42 | -202.40 | -195.99 | -191.42 | -151.29 |
| Normalized Diluted EPS | -32.08 | -123.31 | -119.36 | -115.53 | -94.55 |
| Average Basic Shares Outstanding | 3.43M | 2.27M | 1.21M | 265.90K | 41.00K |
| Average Diluted Shares Outstanding | 3.43M | 2.27M | 1.21M | 265.90K | 41.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |